Brief: Syncona Says Beacon Therapeutics Delivers Positive Topline Result In Phase II/III Vista Trial
21/09/2026 07:28
BRIEF-Syncona Says Beacon Therapeutics Delivers Positive Topline Result In Phase II/III Vista Trial Sept 21 (Reuters) - Syncona Ltd SYNCS.L:
SYNCONA LIMITED - BEACON DELIVERS POSITIVE TOPLINE PII/III RESULTS
SYNCONA - BEACON THERAPEUTICS DELIVERS POSITIVE TOPLINE RESULT IN PHASE II/III VISTA TRIAL
SYNCONA - BEACON TO INITIATE PRE-SUBMISSION DISCUSSIONS WITH GLOBAL REGULATORY AUTHORITIES
SYNCONA - BEACON TO INITIATE ROLLING BLA SUBMISSION LATER THIS YEAR
SYNCONA - LARU-ZOVA MEETS FDA-ENDORSED PRIMARY ENDPOINT WITH STATISTICALLY SIGNIFICANT LLVA
Source text: ID:nRSU5488Va
Further company coverage: SYNCS.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Syncona
See all newsBrief: Syncona Reports Net Assets Of £1.07 Billion, Nav Per Share Of 175.7p, 3.0% Return For Six Months Ended Sept 30, 2026
Syncona Limited - Half-year Report
Syncona Limited - Holding(s) in Company
Brief: Syncona Commits $10.10 Million To OMass $310 Million Series C Financing
Syncona Limited - OMass raises $310 million in Series C financing